Agios Licenses Next-Gen SYK Inhibitor Cevidoplenib for ITP, Commits $25M Upfront
AGIO sits 31% above its 52-week low of $22.24.
Summary
Agios Pharmaceuticals secured exclusive global rights to cevidoplenib, a next-generation SYK inhibitor for immune thrombocytopenia (ITP), from Oscotec. The deal includes a $25 million upfront payment and up to $140 million in potential development and regulatory milestones. This strategic move expands Agios's rare hematology pipeline into ITP, building on recent positive developments for its lead product, PYRUKYND. Cevidoplenib, which has Orphan Drug Designation, showed clinically meaningful platelet responses in Phase 2 secondary endpoints, and Agios plans to initiate Phase 3 development in the first half of 2028. This represents a material investment in a new growth area for the company.
At the time of this announcement, AGIO was trading at $29.14 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $22.24 to $46.00. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.